Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21458603 | 1.00 | MEN1 (0.38) | MEN1KMT2A | |
| SCHEMBL21458820 | 1.00 | MEN1 (0.38) | MEN1KMT2A | |
| SCHEMBL21472362 | 0.87 | NR1H2 (0.34) | MEN1KMT2A | |
| SCHEMBL21471790 | 0.87 | NR1H2 (0.34) | MEN1KMT2A | |
| SCHEMBL21472054 | 0.87 | NR1H2 (0.34) | MEN1KMT2A | |
| SCHEMBL21110990 | 0.83 | MEN1 (0.33) | MEN1KMT2A | |
| SCHEMBL376846 | 0.83 | MEN1 (0.33) | MEN1KMT2A | |
| SCHEMBL21458765 | 0.82 | MEN1 (0.33) | MEN1KMT2A | |
| SCHEMBL22973117 | 0.82 | MEN1 (0.33) | MEN1KMT2A | |
| SCHEMBL22973085 | 0.82 | MEN1 (0.33) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4132655-A1 | COMPOUNDS AND METHODS FOR TARGETED DEGRADATION OF KRAS | Arvinas Operations, Inc. (US) | 2023-02-15 | — | — | EP | disclosed |
| US-20220402907-A1 | MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | YALE UNIVERSITY | 2022-12-22 | — | — | US | disclosed |
| US-11161841-B2 | Modulators of proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2021-11-02 | — | — | US | disclosed |
| EP-3774777-A2 | MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | Arvinas Operations, Inc. (US) | 2021-02-17 | — | — | EP | disclosed |
| US-20190315732-A1 | MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2019-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190315732-A1 | MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | MDM2, CRBN, VHL | MEN1 2058/4885KMT2A 1443/4885 |
| US-20220402907-A1 | MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | MDM2, CRBN, VHL | MEN1 2058/4885KMT2A 1443/4885 |
| US-11161841-B2 | Modulators of proteolysis and associated methods of use | MDM2, CRBN, VHL | MEN1 2058/4885KMT2A 1443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.